伐昔洛韦对比阿昔洛韦治疗带状疱疹疗效和安全性的Meta分析

发布时间：2018-05-31 05:54

本文选题：伐昔洛韦 + 阿昔洛韦　；参考：《中国药房》2017年30期

【摘要】：目的:系统评价伐昔洛韦对比阿昔洛韦治疗带状疱疹的疗效和安全性,为临床提供循证参考。方法:计算机检索PubMed、Medline、中文科技期刊数据库、相关期刊论文和万方数据库,纳入伐昔洛韦(试验组)对比阿昔洛韦(对照组)治疗带状疱疹的随机对照试验(RCT),按照Cochrane系统评价员手册5.1.0评价纳入研究的质量并提取资料后,采用RevMan 5.3统计软件进行Meta分析。结果:共纳入12项RCT,合计1 059例患者。Meta分析结果显示,试验组患者总有效率[OR=4.64,95%CI(2.99,7.20),P0.001]和治愈率[OR=2.93,95%CI(2.13,4.03),P0.001]均显著高于对照组,后遗神经痛发生率[OR=0.39,95%CI(0.22,0.69),P=0.001]显著低于对照组,差异均有统计学意义。两组患者不良反应发生率比较,差异无统计学意义[OR=0.79,95%CI(0.49,1.29),P=0.35]。结论:伐昔洛韦治疗带状疱疹疗效优于阿昔洛韦,可明显降低患者后遗神经痛发生率,两者安全性相当。
[Abstract]:Objective: to evaluate the efficacy and safety of valciclovir compared with acyclovir in the treatment of herpes zoster. Methods: PubMedine Medline, Chinese scientific and technological journal database, full text database of Chinese journal and Wanfang database were searched by computer. A randomized controlled trial of valciclovir (trial group) for herpes zoster treated with acyclovir (control group) was conducted. The quality of the study was evaluated according to the Cochrane system evaluator's manual 5.1.0, and the data were extracted. The Meta was analyzed by RevMan 5.3 statistical software. Results: a total of 10 59 RCTs were included. Meta-analysis showed that the total effective rate [OR4.6495 CIQ 2.997.20g / P0.001] and cure rate [OR2.9395CIN 2.134.03P0.001] were significantly higher than those in the control group, and the incidence of residual neuralgia [OR0.3995CIT 0.220.69P0.001] was significantly lower than that of the control group (P 0.001). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: valaciclovir is superior to acyclovir in the treatment of herpes zoster.
【作者单位】：西安医学院第一附属医院;
【基金】：陕西省科技技术研究发展计划项目(No.2015SF080) 陕西省教育厅科学研究项目(No.14JK1628)
【分类号】：R752.12

【相似文献】